Our Big Idea: An Antibacterial Silver Bullet

Our mission is to prove our disruptive new "peptoid" antibiotics destroy humanity's top threat - highly infectious pandemic bacteria - called drug resistant bacteria. Maxwell's antibiotics have been shown by multiple independent labs (including Stanford, NYU, US Department of Energy and the CDC) to be rapid killers of the worst antibiotic-resistant bacteria. These labs show Maxwell peptoids are highly selective for pathogens over human cells, are biostable, effective at low doses, and rapidly destroy bacterial biofilm defenses. We are in preclinical stage now, preparing for human trials.

Halting Bacterial Resistance

Maxwell's disruptive new synthetic peptoid drug class is a functional mimic of Human Cathelicidin Antimicrobial Peptide (CAMP) also known as LL-37. For over 500 million years, LL-37 has successfully defended mammals against pathogens without allowing bacteria to evolve significant resistance. Mimicking LL-37, our peptoids enter the bacteria, keeping the membrane intact so that nothing can escape, and flocculates on all internal bacterial organelles and DNA - the equivalent of injecting a sticky glue into the internal gears of the bacteria. This, in addition to the extremely rapid killing action, disrupts the bacteria's ability to educate other bacteria on how it was killed. This discovery may have implications for almost every form of medical technology.

Resistant Super Bugs: The Time is Now

Families around the world will face imminent threat from antimicrobial resistant (AMR) super bugs without urgent and meaningful action towards a revolutionary new class of antimicrobials. The World Health Organization rates this problem as urgent and is one of the defining issues of our time.

Each year in the U.S., at least 2 million people get an antibiotic-resistant infection. Globally, billions of people are now infected with drug-resistant bacteria. These bacteria are now in the United States. Without access to next generation antibiotics that destroy bacteria's resistance to drugs, this pandemic will become a historic disaster.

Our peptoids have been shown by multiple independent labs to demonstrate broad-spectrum, extremely rapid antimicrobial killing kinetics against the 45 AMR bacteria tested-to-date, including drug resistant tuberculosis, drug resistant Pseudomonas aeruginosa, Methicillin-resistant Staphylococcus aureus (MRSA), any many other resistant ESKAPE bacteria.

Our peptoids' novel mode of action involves a flocculation and rigidification of internal cellular organelles, with minimal disruption of the cellular membrane mitigating horizontal transfer of microbial genetic information and appears to break the evolution of antimicrobial resistance.